Skip to main content

Articles

Page 4 of 48

  1. Patients with diabetes are at increased risk of developing chronic limb-threatening ischemia (CLTI) due to peripheral arterial disease, and this often results in lower extremity amputation (LEA). Little is kno...

    Authors: Ariel Fangting Ying, Tjun Yip Tang, Aizhen Jin, Tze Tec Chong, Derek John Hausenloy and Woon-Puay Koh
    Citation: Cardiovascular Diabetology 2022 21:7
  2. Fetuin-A is a hepatokine which has the capacity to prevent vascular calcification. Moreover, it is linked to the induction of metabolic dysfunction, insulin resistance and associated with increased risk of dia...

    Authors: Anna Birukov, Elli Polemiti, Susanne Jäger, Norbert Stefan and Matthias B. Schulze
    Citation: Cardiovascular Diabetology 2022 21:6
  3. Systemic inflammatory processes plausibly contribute to the development of cardiovascular complications, causing increased morbidity and mortality in type 2 diabetes. Circulating inflammatory markers, i.e., in...

    Authors: A. M. Wegeberg, T. Okdahl, S. Riahi, N. Ejskjaer, F. Pociot, J. Størling, B. Brock and C. Brock
    Citation: Cardiovascular Diabetology 2022 21:5
  4. In patients with type 2 diabetes (T2D) sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve glycaemic control as well as cardiovascular and renal outcomes. Their effects on l-arginine (Arg) related risk mar...

    Authors: Arne Gessner, Anna Gemeinhardt, Agnes Bosch, Dennis Kannenkeril, Christian Staerk, Andreas Mayr, Martin F. Fromm, Roland E. Schmieder and Renke Maas
    Citation: Cardiovascular Diabetology 2022 21:4
  5. With the advancement of the world population aging, more attention should be paid to the prognosis of elderly patients with acute coronary syndrome (ACS). Triglyceride-glucose (TyG) index is a reliable indicat...

    Authors: Yang Jiao, Yongkang Su, Jian Shen, Xiaoling Hou, Ying Li, Jihang Wang, Bing Liu, Dongfeng Qiu, Zhijun Sun, Yundai Chen, Qing Xi, Mingzhi Shen and Zhenhong Fu
    Citation: Cardiovascular Diabetology 2022 21:3
  6. Previous studies suggested an elevated risk of venous thromboembolism (VTE) among patients with type 2 diabetes mellitus (T2DM), with a possible sex difference. The impact of glycemic control on the risk of VT...

    Authors: Sarah H. R. Charlier, Christian Meier, Susan S. Jick, Christoph R. Meier and Claudia Becker
    Citation: Cardiovascular Diabetology 2022 21:2
  7. The effect of comorbid hypertension and type 2 diabetes mellitus (T2DM) on coronary artery plaques examined by coronary computed tomography angiography (CCTA) is not fully understood. We aimed to comprehensive...

    Authors: Yu Jiang, Yuan Li, Ke Shi, Jin Wang, Wen-Lei Qian, Wei-Feng Yan, Tong Pang and Zhi-Gang Yang
    Citation: Cardiovascular Diabetology 2022 21:1
  8. Elevated blood pressure among adolescents has been shown to be associated with future adverse cardiovascular outcomes and early onset diabetes. Most data regarding systolic and diastolic blood pressure trends ...

    Authors: Boris Fishman, Yair Zloof, Omri Orr, Avishai M. Tsur, Ariel Furer, Ma’ayan Omer Gilon, Gabriel Chodick, Adi Leiba, Estela Derazne, Dorit Tzur, Arnon Afek, Ehud Grossman and Gilad Twig
    Citation: Cardiovascular Diabetology 2021 20:242
  9. Insulin-treated patients with type 2 diabetes (T2D) are at risk of hypoglycemia, which is associated with an increased risk of cardiovascular disease and mortality. Using a long-term monitoring approach, we in...

    Authors: Andreas Andersen, Jonatan I. Bagger, Samuel K. Sørensen, Maria P. A. Baldassarre, Ulrik Pedersen-Bjergaard, Julie L. Forman, Gunnar Gislason, Tommi B. Lindhardt, Filip K. Knop and Tina Vilsbøll
    Citation: Cardiovascular Diabetology 2021 20:241
  10. Post-stroke functional recovery is severely impaired by type 2 diabetes (T2D). This is an important clinical problem since T2D is one of the most common diseases. Because weight loss-based strategies have been...

    Authors: Dimitra Karampatsi, Alexander Zabala, Ulrika Wilhelmsson, Doortje Dekens, Ellen Vercalsteren, Martin Larsson, Thomas Nyström, Milos Pekny, Cesare Patrone and Vladimer Darsalia
    Citation: Cardiovascular Diabetology 2021 20:240
  11. Evidence is limited regarding the association of healthy lifestyle including sleep pattern with the risk of complicated type 2 diabetes mellitus (T2DM) among patients with hypertension. We aimed to investigate...

    Authors: Zimin Song, Ruotong Yang, Wenxiu Wang, Ninghao Huang, Zhenhuang Zhuang, Yuting Han, Lu Qi, Ming Xu, Yi-da Tang and Tao Huang
    Citation: Cardiovascular Diabetology 2021 20:239
  12. The enhanced thrombotic milieu in diabetes contributes to increased risk of vascular events. Aspirin, a key antiplatelet agent, has inconsistent effects on outcomes in diabetes and the best dosing regimen rema...

    Authors: William A. E. Parker, Rebecca Sagar, Zeyad Kurdee, Fladia Hawkins, Khalid M. Naseem, Peter J. Grant, Robert F. Storey and Ramzi A. Ajjan
    Citation: Cardiovascular Diabetology 2021 20:238
  13. Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) leads to multiple metabolic changes, reduction in glucose levels and body weight are well established. In people with type 2 diabetes, GLP-1...

    Authors: J. Jendle, T. Hyötyläinen, M. Orešič and T. Nyström
    Citation: Cardiovascular Diabetology 2021 20:237
  14. It has been suggested that sodium–glucose cotransporter 2 (SGLT-2) inhibitors reduce the cardiorenal risk in patients with type 2 diabetes (T2D). The purpose of this study is to provide an update of all large ...

    Authors: Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Maria Ida Maiorino and Katherine Esposito
    Citation: Cardiovascular Diabetology 2021 20:236
  15. Intensive glycemic control is generally recommended for diabetic patients to reduce complications. However, the role of glycemic control in the mortality in diabetic patients with acute myocardial infarction (...

    Authors: Ik Jun Choi, Eun Ho Choo, Hwa Jung Kim, Sungmin Lim, Donggyu Moon, Kwan Yong Lee, Byung-Hee Hwang, Chan Joon Kim, Mahn-Won Park, Jong-Min Lee, Chul Soo Park, Hee-Yeol Kim, Ki-Dong Yoo, Doo Soo Jeon, Wook Sung Chung, Min Chul Kim…
    Citation: Cardiovascular Diabetology 2021 20:234
  16. Low C-peptide levels, indicating beta-cell dysfunction, are associated with increased within-day glucose variation and hypoglycemia. In advanced type 2 diabetes, severe hypoglycemia and increased glucose varia...

    Authors: Juraj Koska, Daniel S. Nuyujukian, Gideon D. Bahn, Jin J. Zhou and Peter D. Reaven
    Citation: Cardiovascular Diabetology 2021 20:232
  17. Incidence rates of cardiovascular disease (CVD) are increasing, partly driven by the diabetes epidemic. Novel prediction tools and modifiable treatment targets are needed to enhance risk assessment and managem...

    Authors: Parag Anilkumar Chevli, Barry I. Freedman, Fang-Chi Hsu, Jianzhao Xu, Megan E. Rudock, Lijun Ma, John S. Parks, Nicholette D. Palmer and Michael D. Shapiro
    Citation: Cardiovascular Diabetology 2021 20:231
  18. Atrial fibrillation (AF) is a common arrhythmia classified as paroxysmal and non-paroxysmal. Non-paroxysmal AF is associated with an increased risk of complications. Diabetes contributes to AF initiation, yet ...

    Authors: Fadi Alijla, Chepkoech Buttia, Tobias Reichlin, Salman Razvi, Beatrice Minder, Matthias Wilhelm, Taulant Muka, Oscar H. Franco and Arjola Bano
    Citation: Cardiovascular Diabetology 2021 20:230
  19. The THEMIS randomized trial compared ticagrelor plus aspirin versus placebo plus aspirin for patients with stable coronary artery disease and type 2 diabetes mellitus (CAD-T2DM), and without prior myocardial i...

    Authors: Patrick Blin, Patrice Darmon, Patrick Henry, Estelle Guiard, Marie-Agnès Bernard, Caroline Dureau-Pournin, Hélène Maizi, Florence Thomas-Delecourt, Régis Lassalle, Cécile Droz-Perroteau and Nicholas Moore
    Citation: Cardiovascular Diabetology 2021 20:229
  20. Dyslipidemia is a major cardiovascular risk factor and common in diabetes patients. Most guidelines focus on optimal lipid levels, while variation of lipid profiles is far less discussed. This study aims to in...

    Authors: Mu-Cyun Wang, Chia-Ing Li, Chiu-Shong Liu, Chih-Hsueh Lin, Shing-Yu Yang, Tsai-Chung Li and Cheng-Chieh Lin
    Citation: Cardiovascular Diabetology 2021 20:228
  21. Dysglycaemia is associated with overall cardiovascular disease even at prediabetes levels. The aim of this study was to explore the association between glucose levels and future risk of developing atrial fibri...

    Authors: Viktor Lind, Niklas Hammar, Pia Lundman, Leif Friberg, Mats Talbäck, Göran Walldius and Anna Norhammar
    Citation: Cardiovascular Diabetology 2021 20:227
  22. Atrial fibrillation (AF) is prevalent in patients with type 2 diabetes mellitus (T2DM). Obesity commonly accompanies T2DM, and increases the risk of AF. However, the dose-relationship between body mass index (...

    Authors: Jung-Chi Hsu, Yen-Yun Yang, Shu-Lin Chuang, Yi-Wei Chung, Chih-Hsien Wang and Lian-Yu Lin
    Citation: Cardiovascular Diabetology 2021 20:226
  23. Incretin hormones are peptides released in the intestine in response to the presence of nutrients in its lumen. The main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polyp...

    Authors: Enrique Z. Fisman and Alexander Tenenbaum
    Citation: Cardiovascular Diabetology 2021 20:225
  24. Epicardial adipose tissue (EAT) is considered a novel diagnostic marker for cardiometabolic disease. This study aimed to evaluate whether EAT volume was associated with stress-induced myocardial ischemia in as...

    Authors: Emmanuel Cosson, Minh Tuan Nguyen, Imen Rezgani, Narimane Berkane, Sara Pinto, Hélène Bihan, Sopio Tatulashvili, Malak Taher, Meriem Sal, Michael Soussan, Pierre-Yves Brillet and Paul Valensi
    Citation: Cardiovascular Diabetology 2021 20:224
  25. Biomarkers may contribute to improved cardiovascular risk estimation. Glycated hemoglobin A1c (HbA1c) is used to monitor the quality of diabetes treatment. Its strength of association with cardiovascular outcomes...

    Authors: Christoph Sinning, Nataliya Makarova, Henry Völzke, Renate B. Schnabel, Francisco Ojeda, Marcus Dörr, Stephan B. Felix, Wolfgang Koenig, Annette Peters, Wolfgang Rathmann, Ben Schöttker, Hermann Brenner, Giovanni Veronesi, Giancarlo Cesana, Paolo Brambilla, Tarja Palosaari…
    Citation: Cardiovascular Diabetology 2021 20:223
  26. We aimed to compare cardiovascular outcomes of patients with type 2 diabetes (T2D) who initiated GLP-1 receptor agonists (GLP-1RA) or basal insulin (BI) under routine care.

    Authors: Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro and Gian Paolo Fadini
    Citation: Cardiovascular Diabetology 2021 20:222
  27. RBP4 is an adipokine with an established role in atherosclerosis, while adiponectin has unique anti-inflammatory properties. We investigated the association of RBP4 and adiponectin with the presence of symptom...

    Authors: Nikolaos P. E. Kadoglou, Emmanouil Korakas, Christos Karkos, Eirini Maratou, Ioannis Kanonidis, Panagiotis Plotas, Nikolaos Papanas, Paraskevi Moutsatsou, Ignatios Ikonomidis and Vaia Lambadiari
    Citation: Cardiovascular Diabetology 2021 20:221
  28. Type 2 diabetes is a condition associated with a state of low-grade inflammation caused by adipose tissue dysfunction and insulin resistance. High sensitive-CRP (hs-CRP) is a marker for systemic low-grade infl...

    Authors: Shahnam Sharif, Y. Van der Graaf, M. J. Cramer, L. J. Kapelle, G. J. de Borst, Frank L. J. Visseren and Jan Westerink
    Citation: Cardiovascular Diabetology 2021 20:220
  29. Recent studies indicated that sodium glucose cotransporter (SGLT)2 inhibition increases levels of ketone bodies in the blood in patients with type 1 and 2 diabetes. Other studies suggested that in patients wit...

    Authors: R. Pietschner, J. Kolwelter, A. Bosch, K. Striepe, S. Jung, D. Kannenkeril, C. Ott, M. Schiffer, S. Achenbach and R. E. Schmieder
    Citation: Cardiovascular Diabetology 2021 20:219
  30. Type 2 diabetes is one of the most relevant risk factors for heart failure, the prevalence of which is increasing worldwide. The aim of the review is to highlight the current perspectives of the pathophysiolog...

    Authors: Antonio Ceriello, Doina Catrinoiu, Chanchal Chandramouli, Francesco Cosentino, Annique Cornelia Dombrowsky, Baruch Itzhak, Nebojsa Malić Lalic, Francesco Prattichizzo, Oliver Schnell, Petar M. Seferović, Paul Valensi and Eberhard Standl
    Citation: Cardiovascular Diabetology 2021 20:218
  31. Diabetes is associated with adverse outcomes after percutaneous coronary intervention with drug-eluting stents (DES), but for prediabetes this association has not been definitely established. Furthermore, in p...

    Authors: Eline H. Ploumen, Tineke H. Pinxterhuis, Paolo Zocca, Ariel Roguin, Rutger L. Anthonio, Carl E. Schotborgh, Edouard Benit, Adel Aminian, Peter W. Danse, Carine J. M. Doggen, Clemens von Birgelen and Marlies M. Kok
    Citation: Cardiovascular Diabetology 2021 20:217
  32. Authors: Michal Herman-Edelstein, Tali Guetta, Amir Barnea, Maayan Waldman, Naomi Ben-Dor, Yaron D. Barac, Ran Kornowski, Michael Arad, Edith Hochhauser and Dan Aravot
    Citation: Cardiovascular Diabetology 2021 20:216

    The original article was published in Cardiovascular Diabetology 2021 20:90

  33. Type 2 diabetes mellitus (T2DM) is a major risk factor for coronary artery disease and myocardial infarction (MI). The interaction of diabetic cardiomyopathy and MI scars on myocardial deformation in T2DM pati...

    Authors: Yue Gao, Hua-yan Xu, Ying-kun Guo, Xiao-ling Wen, Rui Shi, Yuan Li and Zhi-gang Yang
    Citation: Cardiovascular Diabetology 2021 20:215
  34. It has been demonstrated that patients with type 2 diabetes mellitus (DM) is associated with increased cardiovascular risk. However, little is known regarding the long-term prognosis in diabetic patients who e...

    Authors: Hui-Wen Zhang, Jing-Lu Jin, Ye-Xuan Cao, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Rui-Xia Xu, Qian Dong and Jian-Jun Li
    Citation: Cardiovascular Diabetology 2021 20:214
  35. The treatment effects on hospitalization for heart failure (hHF) from sodium-glucose cotransporter 2 (SGLT2) inhibitors may vary among type 2 diabetes (T2D) patients depending on whether or not they have estab...

    Authors: Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Shang-Hung Chang, Ming-Jui Hung, Yuk-Ying Chan and Edward Chia-Cheng Lai
    Citation: Cardiovascular Diabetology 2021 20:213
  36. Left ventricular (LV) involvement in diabetic cardiomyopathy has been reported; however, only limited data exist on right ventricular (RV) involvement. Therefore, our purpose was to investigate RV systolic dys...

    Authors: Saki Todo, Hidekazu Tanaka, Yuki Yamauchi, Shun Yokota, Yasuhide Mochizuki, Hiroaki Shiraki, Kentaro Yamashita, Ayu Shono, Makiko Suzuki, Keiko Sumimoto, Yusuke Tanaka, Yushi Hirota, Wataru Ogawa and Ken-ichi Hirata
    Citation: Cardiovascular Diabetology 2021 20:212
  37. Stress-induced hyperglycaemia at time of hospital admission has been linked to worse prognosis following acute myocardial infarction (AMI). In addition to glucose, other glucose-related indices, such as HbA1c,...

    Authors: Ching-Hui Sia, Mervyn Huan-Hao Chan, Huili Zheng, Junsuk Ko, Andrew Fu-Wah Ho, Jun Chong, David Foo, Ling-Li Foo, Patrick Zhan-Yun Lim, Boon Wah Liew, Ping Chai, Tiong-Cheng Yeo, Huay-Cheem Tan, Terrance Chua, Mark Yan-Yee Chan, Jack Wei Chieh Tan…
    Citation: Cardiovascular Diabetology 2021 20:211
  38. Besides providing reassurance about cardiovascular (CV) safety of newer diabetes drugs, cardiovascular outcome trials (CVOTs) have also shown encouraging benefits on some CV endpoints. The contribution of the ...

    Authors: Maria Ida Maiorino, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito and Dario Giugliano
    Citation: Cardiovascular Diabetology 2021 20:210
  39. The combination of diabetes mellitus (DM) and chronic kidney disease (CKD) is associated with a high risk of mortality. Annual assessment of the estimated glomerular filtration rate (eGFR) is recommended for p...

    Authors: Yu-Shan Chang, Yu-Hsuan Li and I-Te Lee
    Citation: Cardiovascular Diabetology 2021 20:209
  40. Advanced glycation end-products, indicated by skin autofluorescence (SAF) levels, could be prognostic predictors of all-cause and cardiovascular mortality in patients with diabetes mellitus (DM) and renal dise...

    Authors: Mitsuhiro Kunimoto, Miho Yokoyama, Kazunori Shimada, Tomomi Matsubara, Tatsuro Aikawa, Shohei Ouchi, Kosuke Fukao, Tetsuro Miyazaki, Kei Fujiwara, Abidan Abulimiti, Akio Honzawa, Akie Shimada, Taira Yamamoto, Atsushi Amano, Masakazu Saitoh, Tomoyuki Morisawa…
    Citation: Cardiovascular Diabetology 2021 20:208
  41. Previous studies suggested an adverse association between higher fasting blood glucose (FBG) variability and cardiovascular disease (CVD). Lifetime risk provides an absolute risk assessment during the remainde...

    Authors: Jianing Bi, Lulu Song, Lulin Wang, Mingyang Wu, Shouhua Chen, Youjie Wang, Shouling Wu and Yaohua Tian
    Citation: Cardiovascular Diabetology 2021 20:207
  42. Insulin resistance (IR) is a known risk factor for cardiovascular disease (CVD) in non-diabetic patients through the association of hyperglycemia or associated metabolic factors. The triglyceride glucose (TyG)...

    Authors: Ya-Wen Lu, Chun-Chin Chang, Ruey-Hsing Chou, Yi-Lin Tsai, Li-Kuo Liu, Liang-Kung Chen, Po-Hsun Huang and Shing-Jong Lin
    Citation: Cardiovascular Diabetology 2021 20:206
  43. Cardiovascular disease (CVD) remains the leading cause of death in patients with type 2 diabetes (T2D). Older age, prior heart failure (HF) and CV events, peripheral artery disease, and kidney complications ca...

    Authors: Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, Giuseppe Bellastella and Katherine Esposito
    Citation: Cardiovascular Diabetology 2021 20:205
  44. With emerging evidence on the efficacy of adding dapagliflozin to standard care for patients with heart failure with reduced ejection fraction (HFrEF), this study assessed the cost-effectiveness of add-on dapa...

    Authors: Chia-Te Liao, Chun-Ting Yang, Han Siong Toh, Wei-Ting Chang, Hung-Yu Chang, Fang-Hsiu Kuo, Mei-Chuan Lee, Yi-Ming Hua, Hsin-Ju Tang, Carol Strong and Huang-Tz Ou
    Citation: Cardiovascular Diabetology 2021 20:204
  45. To assess the effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) for type 2 diabetes on kidney outcomes stratified by patient baseline estimated glomerular filtration rate (eGFR) levels (i.e., eGFR...

    Authors: Fang-Ju Lin, Chi-Chuan Wang, Chien-Ning Hsu, Chen-Yi Yang, Chih-Yuan Wang and Huang-Tz Ou
    Citation: Cardiovascular Diabetology 2021 20:203
  46. Insulin resistance contributes to the development of type 2 diabetes (T2D) and is also a cardiovascular risk factor. The aim of this study was to investigate the potential association between insulin resistanc...

    Authors: Alexander Zabala, Vladimer Darsalia, Marcus Lind, Ann-Marie Svensson, Stefan Franzén, Björn Eliasson, Cesare Patrone, Magnus Jonsson and Thomas Nyström
    Citation: Cardiovascular Diabetology 2021 20:202
  47. Previous studies reported the prognostic value of the atherogenic index of plasma (AIP) in the course of atherosclerosis and other cardiovascular diseases (CVDs). Still, the predictive utility of the AIP is un...

    Authors: Liyao Fu, Ying Zhou, Jiaxing Sun, Zhaowei Zhu, Zhenhua Xing, Shenghua Zhou, Yongjun Wang and Shi Tai
    Citation: Cardiovascular Diabetology 2021 20:201
  48. Empagliflozin is a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor used to lower blood sugar in adults with type 2 diabetes. Empagliflozin also exerts cardioprotective effects independent from gluco...

    Authors: Zhaoyang Hu, Feng Ju, Lei Du and Geoffrey W. Abbott
    Citation: Cardiovascular Diabetology 2021 20:199

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics